Skip to contentM
Mangoceuticals, Inc.
M
MGRXMangoceuticals, Inc. Q1 2025 · 10-Q
Revenue$109.31K$109.31K−48.9% vs Q1 2024 Net Income-$4.84M-$4.84MN/M vs Q1 2024 EPS Diluted-$1.12-$1.12N/M vs Q1 2024 Gross Profit$62,064−57.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
Operating Cash Flow-$2,274,781N/M Margins · derivedGross margin56.8%−12.1 pt vs Q1 2024
Operating margin-4186.8%−3080.9 pt vs Q1 2024
Net margin-4427.4%−3321.5 pt vs Q1 2024
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end